Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors

T-cell receptor (TCR) redirected T cells are considered as the next generation of care for the treatment of numerous solid tumors. KRAS mutations are driver neoantigens that are expressed in over 25% of all cancers and are thus regarded as ideal targets for Adoptive Cell Therapy (ACT). We have isola...

Full description

Bibliographic Details

Published in:	OncoImmunology
Main Authors:	Pierre Dillard, Nicholas Casey, Sylvie Pollmann, Patrik Vernhoff, Gustav Gaudernack, Gunnar Kvalheim, Sébastien Wälchli, Else Marit Inderberg
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2021-01-01
Subjects:	immunotherapy adoptive cell therapy tcr kras
Online Access:	http://dx.doi.org/10.1080/2162402X.2021.1936757